Multiplicity and the Marginal Benefits of Bevacizumab in Malignant Solid Tumours
Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
Curr. Oncol. 2019, 26(6), 791-792; https://doi.org/10.3747/co.26.4845
Submission received: 11 September 2019
/
Revised: 7 October 2019
/
Accepted: 5 November 2019
/
Published: 1 December 2019
Abstract
Although clinical trials of novel medications have historically been individually interpreted, there is increasing recognition that trials should be considered to be part of a broader clinical trials agenda or portfolio […]
Share and Cite
MDPI and ACS Style
Prasad, V. Multiplicity and the Marginal Benefits of Bevacizumab in Malignant Solid Tumours. Curr. Oncol. 2019, 26, 791-792. https://doi.org/10.3747/co.26.4845
AMA Style
Prasad V. Multiplicity and the Marginal Benefits of Bevacizumab in Malignant Solid Tumours. Current Oncology. 2019; 26(6):791-792. https://doi.org/10.3747/co.26.4845
Chicago/Turabian StylePrasad, Vinay. 2019. "Multiplicity and the Marginal Benefits of Bevacizumab in Malignant Solid Tumours" Current Oncology 26, no. 6: 791-792. https://doi.org/10.3747/co.26.4845
